APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anaplastic Lymphoma Kinase ALK Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Anaplastic Lymphoma Kinase ALK Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025194 pages

Choose your research edition.

Industry ResearchAnaplastic Lymphoma Kinase ALK Inhibitor Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Anaplastic Lymphoma Kinase ALK Inhibitor Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Anaplastic Lymphoma Kinase ALK Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anaplastic Lymphoma Kinase ALK Inhibitor Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Anaplastic Lymphoma Kinase ALK Inhibitor Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Anaplastic Lymphoma Kinase ALK Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Anaplastic Lymphoma Kinase ALK Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anaplastic Lymphoma Kinase ALK Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anaplastic Lymphoma Kinase ALK Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Anaplastic Lymphoma Kinase ALK Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Anaplastic Lymphoma Kinase ALK Inhibitor include Takeda Pharmaceuticals, Novartis, Merck, Roche, Pfizer, AstraZeneca, Turning Point Therapeutics, GlaxoSmithKline and Betta Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anaplastic Lymphoma Kinase ALK Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anaplastic Lymphoma Kinase ALK Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anaplastic Lymphoma Kinase ALK Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anaplastic Lymphoma Kinase ALK Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

Anaplastic Lymphoma Kinase ALK Inhibitor Segment by Company

Takeda Pharmaceuticals

Novartis

Merck

Roche

Pfizer

AstraZeneca

Turning Point Therapeutics

GlaxoSmithKline

Betta Pharmaceuticals

Astellas Pharma

Anaplastic Lymphoma Kinase ALK Inhibitor Segment by Type

First Generation ALK Inhibitor

Second Generation ALK Inhibitor

Third Generation ALK Inhibitor

Anaplastic Lymphoma Kinase ALK Inhibitor Segment by Application

Hospital Pharmacy

Retail Pharmacy

Others

Anaplastic Lymphoma Kinase ALK Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anaplastic Lymphoma Kinase ALK Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anaplastic Lymphoma Kinase ALK Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anaplastic Lymphoma Kinase ALK Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anaplastic Lymphoma Kinase ALK Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anaplastic Lymphoma Kinase ALK Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Anaplastic Lymphoma Kinase ALK Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Anaplastic Lymphoma Kinase ALK Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Anaplastic Lymphoma Kinase ALK Inhibitor Industry Trends Table 2. Anaplastic Lymphoma Kinase ALK Inhibitor Industry Drivers Table 3. Anaplastic Lymphoma Kinase ALK Inhibitor Industry Opportunities and Challenges Table 4. Anaplastic Lymphoma Kinase ALK Inhibitor Industry Restraints Table 5. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Manufacturers Table 9. Global Anaplastic Lymphoma Kinase ALK Inhibitor Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Anaplastic Lymphoma Kinase ALK Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Anaplastic Lymphoma Kinase ALK Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturers, Product Type & Application Table 13. Global Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Anaplastic Lymphoma Kinase ALK Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of First Generation ALK Inhibitor Table 17. Major Manufacturers of Second Generation ALK Inhibitor Table 18. Major Manufacturers of Third Generation ALK Inhibitor Table 19. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2021-2026) & (K Units) Table 21. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2027-2032) & (K Units) Table 22. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Type (2021-2026) Table 23. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Type (2027-2032) Table 24. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Type (2021-2026) & (K Units) Table 26. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Type (2027-2032) & (K Units) Table 27. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Type (2021-2026) Table 28. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Pharmacy Table 30. Major Manufacturers of Retail Pharmacy Table 31. Major Manufacturers of Others Table 32. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2021-2026) & (K Units) Table 34. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2027-2032) & (K Units) Table 35. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Application (2021-2026) Table 36. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Application (2027-2032) Table 37. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Application (2021-2026) & (K Units) Table 39. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Application (2027-2032) & (K Units) Table 40. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Application (2021-2026) Table 41. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Application (2027-2032) Table 42. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Region (2021-2026) & (K Units) Table 44. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Region (2021-2026) Table 45. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2021-2026) & (K Units) Table 49. North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2027-2032) & (K Units) Table 50. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2021-2026) & (K Units) Table 52. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2027-2032) & (K Units) Table 59. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Region (2021-2026) Table 63. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Region (2027-2032) Table 64. Takeda Pharmaceuticals Company Information Table 65. Takeda Pharmaceuticals Business Overview Table 66. Takeda Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Takeda Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio Table 68. Takeda Pharmaceuticals Recent Development Table 69. Novartis Company Information Table 70. Novartis Business Overview Table 71. Novartis Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Novartis Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio Table 73. Novartis Recent Development Table 74. Merck Company Information Table 75. Merck Business Overview Table 76. Merck Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Merck Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio Table 78. Merck Recent Development Table 79. Roche Company Information Table 80. Roche Business Overview Table 81. Roche Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Roche Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio Table 83. Roche Recent Development Table 84. Pfizer Company Information Table 85. Pfizer Business Overview Table 86. Pfizer Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Pfizer Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio Table 88. Pfizer Recent Development Table 89. AstraZeneca Company Information Table 90. AstraZeneca Business Overview Table 91. AstraZeneca Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. AstraZeneca Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio Table 93. AstraZeneca Recent Development Table 94. Turning Point Therapeutics Company Information Table 95. Turning Point Therapeutics Business Overview Table 96. Turning Point Therapeutics Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Turning Point Therapeutics Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio Table 98. Turning Point Therapeutics Recent Development Table 99. GlaxoSmithKline Company Information Table 100. GlaxoSmithKline Business Overview Table 101. GlaxoSmithKline Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. GlaxoSmithKline Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio Table 103. GlaxoSmithKline Recent Development Table 104. Betta Pharmaceuticals Company Information Table 105. Betta Pharmaceuticals Business Overview Table 106. Betta Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Betta Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio Table 108. Betta Pharmaceuticals Recent Development Table 109. Astellas Pharma Company Information Table 110. Astellas Pharma Business Overview Table 111. Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio Table 113. Astellas Pharma Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Anaplastic Lymphoma Kinase ALK Inhibitor Distributors List Table 117. Anaplastic Lymphoma Kinase ALK Inhibitor Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Anaplastic Lymphoma Kinase ALK Inhibitor Product Image Figure 2. Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales (2021-2032) & (K Units) Figure 5. Global Anaplastic Lymphoma Kinase ALK Inhibitor Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Anaplastic Lymphoma Kinase ALK Inhibitor Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. First Generation ALK Inhibitor Image Figure 9. Second Generation ALK Inhibitor Image Figure 10. Third Generation ALK Inhibitor Image Figure 11. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Type (2021-2032) Figure 14. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Type (2021-2032) Figure 17. Hospital Pharmacy Image Figure 18. Retail Pharmacy Image Figure 19. Others Image Figure 20. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Application (2021-2032) Figure 23. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Application (2021-2032) Figure 26. North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Country (2021-2032) Figure 28. U.S. Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Country (2021-2032) Figure 33. Germany Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Country (2021-2032) Figure 40. China Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Country (2021-2032) Figure 48. Brazil Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Anaplastic Lymphoma Kinase ALK Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2021-2032) & (US$ Million) Figure 59. North America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2021-2032) & (US$ Million) Figure 61. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Anaplastic Lymphoma Kinase ALK Inhibitor Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Anaplastic Lymphoma Kinase ALK Inhibitor Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • First Generation ALK Inhibitor
  • Second Generation ALK Inhibitor
  • Third Generation ALK Inhibitor
Applications
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others
Companies covered
  • Takeda Pharmaceuticals
  • Novartis
  • Merck
  • Roche
  • Pfizer
  • AstraZeneca
  • Turning Point Therapeutics
  • GlaxoSmithKline
  • Betta Pharmaceuticals
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Dynamics
  1. 2.1 Anaplastic Lymphoma Kinase ALK Inhibitor Industry Trends
  2. 2.2 Anaplastic Lymphoma Kinase ALK Inhibitor Industry Drivers
  3. 2.3 Anaplastic Lymphoma Kinase ALK Inhibitor Industry Opportunities and Challenges
  4. 2.4 Anaplastic Lymphoma Kinase ALK Inhibitor Industry Restraints
3 Anaplastic Lymphoma Kinase ALK Inhibitor Market by Manufacturers
  1. 3.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Manufacturers (2021-2026)
  3. 3.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Anaplastic Lymphoma Kinase ALK Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anaplastic Lymphoma Kinase ALK Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturers, Product Type & Application
  7. 3.7 Global Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anaplastic Lymphoma Kinase ALK Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anaplastic Lymphoma Kinase ALK Inhibitor Tier 1, Tier 2, and Tier 3
4 Anaplastic Lymphoma Kinase ALK Inhibitor Market by Type
  1. 4.1 Anaplastic Lymphoma Kinase ALK Inhibitor Type Introduction
  2. 4.1.1 First Generation ALK Inhibitor
  3. 4.1.2 Second Generation ALK Inhibitor
  4. 4.1.3 Third Generation ALK Inhibitor
  5. 4.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type
  6. 4.2.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2021-2032)
  8. 4.2.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Type (2021-2032)
  9. 4.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Type
  10. 4.3.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Type (2021-2032)
  12. 4.3.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Type (2021-2032)
5 Anaplastic Lymphoma Kinase ALK Inhibitor Market by Application
  1. 5.1 Anaplastic Lymphoma Kinase ALK Inhibitor Application Introduction
  2. 5.1.1 Hospital Pharmacy
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Others
  5. 5.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application
  6. 5.2.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Application (2021-2032)
  8. 5.2.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Application (2021-2032)
  9. 5.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Application
  10. 5.3.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Application (2021-2032)
  12. 5.3.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Application (2021-2032)
6 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Region
  1. 6.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Region (2021-2026)
  4. 6.2.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region
  1. 7.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region
  2. 7.1.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region (2021-2026)
  4. 7.1.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region (2027-2032)
  5. 7.1.4 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2021-2032)
  8. 7.2.2 North America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2021-2032)
  11. 7.3.2 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Roche Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Turning Point Therapeutics
  38. 8.7.1 Turning Point Therapeutics Company Information
  39. 8.7.2 Turning Point Therapeutics Business Overview
  40. 8.7.3 Turning Point Therapeutics Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Turning Point Therapeutics Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
  42. 8.7.5 Turning Point Therapeutics Recent Developments
  43. 8.8 GlaxoSmithKline
  44. 8.8.1 GlaxoSmithKline Company Information
  45. 8.8.2 GlaxoSmithKline Business Overview
  46. 8.8.3 GlaxoSmithKline Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GlaxoSmithKline Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
  48. 8.8.5 GlaxoSmithKline Recent Developments
  49. 8.9 Betta Pharmaceuticals
  50. 8.9.1 Betta Pharmaceuticals Company Information
  51. 8.9.2 Betta Pharmaceuticals Business Overview
  52. 8.9.3 Betta Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Betta Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
  54. 8.9.5 Betta Pharmaceuticals Recent Developments
  55. 8.10 Astellas Pharma
  56. 8.10.1 Astellas Pharma Company Information
  57. 8.10.2 Astellas Pharma Business Overview
  58. 8.10.3 Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
  60. 8.10.5 Astellas Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anaplastic Lymphoma Kinase ALK Inhibitor Value Chain Analysis
  2. 9.1.1 Anaplastic Lymphoma Kinase ALK Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anaplastic Lymphoma Kinase ALK Inhibitor Production Mode & Process
  6. 9.2 Anaplastic Lymphoma Kinase ALK Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anaplastic Lymphoma Kinase ALK Inhibitor Distributors
  9. 9.2.3 Anaplastic Lymphoma Kinase ALK Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst